Dermatofibroma natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(8 intermediate revisions by 3 users not shown)
Line 2: Line 2:
{{Dermatofibroma}}
{{Dermatofibroma}}
{{CMG}};{{AE}}{{Homa}}
{{CMG}};{{AE}}{{Homa}}
==Overview==
In rare cases, [[basal cell carcinoma]] may develop in a dermatofibroma.
==Complications==
* In rare cases, [[basal cell carcinoma]] may develop in a dermatofibroma.
==Overview==
==Overview==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Dermatofibroma usually [[Development|develops]] in the third decade of life, and most of them are [[asymptomatic]]. Common [[complications]] of dermatofibroma are related to [[Excision|excisional]] removing of the [[lesion]] and include, [[bleeding]], [[infection]] and [[scar]]. [[Prognosis]] is generally excellent. Although, in very [[rare]] cases [[metastases]] are seen.
 
OR
 
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
 
OR
 
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==


===Natural History===
===Natural History===
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.  
*Dermatofibroma usually [[Development|develops]] in the third decade of life, and most of them are [[asymptomatic]].<ref name="AgarwalGopinath2017">{{cite journal|last1=Agarwal|first1=Atin|last2=Gopinath|first2=Arun|last3=Tetzlaff|first3=Michael T.|last4=Prieto|first4=Victor G.|title=Phosphohistone-H3 and Ki67|journal=The American Journal of Dermatopathology|volume=39|issue=7|year=2017|pages=504–507|issn=0193-1091|doi=10.1097/DAD.0000000000000690}}</ref><ref name="BuehlerWeisman2017">{{cite journal|last1=Buehler|first1=Darya|last2=Weisman|first2=Paul|title=Soft Tissue Tumors of Uncertain Histogenesis|journal=Clinics in Laboratory Medicine|volume=37|issue=3|year=2017|pages=647–671|issn=02722712|doi=10.1016/j.cll.2017.06.005}}</ref><ref name="HanChang2011">{{cite journal|last1=Han|first1=Tae Young|last2=Chang|first2=Hee Sun|last3=Lee|first3=June Hyun Kyung|last4=Lee|first4=Won-Mi|last5=Son|first5=Sook-Ja|title=A Clinical and Histopathological Study of 122 Cases of Dermatofibroma (Benign Fibrous Histiocytoma)|journal=Annals of Dermatology|volume=23|issue=2|year=2011|pages=185|issn=1013-9087|doi=10.5021/ad.2011.23.2.185}}</ref>
*The symptoms of (disease name) typically develop ___ years after exposure to ___.  
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].


===Complications===
===Complications===
*Common complications of [disease name] include:
*Common [[complications]] of dermatofibroma are related to [[Excision|excisional]] removing of the [[lesion]] and include:<ref>{{Cite journal
**[Complication 1]
| author = [[David J.. Myers]] & [[Eric P.. Fillman]]
**[Complication 2]
| title = Dermatofibroma
**[Complication 3]
| year = 2019
| month =
| pmid = 29262213
|url=|first=|date=|journal=|volume=|pages=|via=}}</ref>
**[[Bleeding]]
**[[Infection]]
**[[Scar]]


===Prognosis===
===Prognosis===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
*[[Prognosis]] is generally excellent. Although, in very [[rare]] cases [[metastases]] are seen.<ref name="RomanoFritchie2017">{{cite journal|last1=Romano|first1=Ryan C.|last2=Fritchie|first2=Karen J.|title=Fibrohistiocytic Tumors|journal=Clinics in Laboratory Medicine|volume=37|issue=3|year=2017|pages=603–631|issn=02722712|doi=10.1016/j.cll.2017.05.007}}</ref>
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Needs content]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Disease]]

Latest revision as of 21:18, 29 July 2020

Dermatofibroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Dermatofibroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dermatofibroma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dermatofibroma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dermatofibroma natural history, complications and prognosis

CDC on Dermatofibroma natural history, complications and prognosis

Dermatofibroma natural history, complications and prognosis in the news

Blogs on Dermatofibroma natural history, complications and prognosis

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Dermatofibroma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]

Overview

Dermatofibroma usually develops in the third decade of life, and most of them are asymptomatic. Common complications of dermatofibroma are related to excisional removing of the lesion and include, bleeding, infection and scar. Prognosis is generally excellent. Although, in very rare cases metastases are seen.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

References

  1. Agarwal, Atin; Gopinath, Arun; Tetzlaff, Michael T.; Prieto, Victor G. (2017). "Phosphohistone-H3 and Ki67". The American Journal of Dermatopathology. 39 (7): 504–507. doi:10.1097/DAD.0000000000000690. ISSN 0193-1091.
  2. Buehler, Darya; Weisman, Paul (2017). "Soft Tissue Tumors of Uncertain Histogenesis". Clinics in Laboratory Medicine. 37 (3): 647–671. doi:10.1016/j.cll.2017.06.005. ISSN 0272-2712.
  3. Han, Tae Young; Chang, Hee Sun; Lee, June Hyun Kyung; Lee, Won-Mi; Son, Sook-Ja (2011). "A Clinical and Histopathological Study of 122 Cases of Dermatofibroma (Benign Fibrous Histiocytoma)". Annals of Dermatology. 23 (2): 185. doi:10.5021/ad.2011.23.2.185. ISSN 1013-9087.
  4. David J.. Myers & Eric P.. Fillman (2019). "Dermatofibroma". PMID 29262213.
  5. Romano, Ryan C.; Fritchie, Karen J. (2017). "Fibrohistiocytic Tumors". Clinics in Laboratory Medicine. 37 (3): 603–631. doi:10.1016/j.cll.2017.05.007. ISSN 0272-2712.